CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: CD8+ T-cell expansions have also been reported in patients undergoing treatment with the promiscuous tyrosine kinase inhibitor dasatinib, which is licensed as a first line therapeutic option in the management of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)11–16.